Clindamycin Hydrochloride Capsules Recalled for Manufacturing Practice Deviations
Glenmark Pharmaceuticals Inc. USA is recalling Clindamycin Hydrochloride Capsules, USP 300mg due to CGMP deviations. The product has been distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II recall with no reported illnesses, injuries, or hospitalizations. The hazard is a manufacturing process deviation rather than a specifically identified safety risk, making this a low-risk, voluntary precautionary recall.
Plain-English summary
Glenmark Pharmaceuticals Inc. USA is recalling Clindamycin Hydrochloride Capsules, USP, 300mg in 100-count bottles. The recall was initiated on March 13, 2025 and remains ongoing.
The reason for the recall is CGMP (Current Good Manufacturing Practice) deviations identified during the manufacturing process. The firm initiated the recall voluntarily.
The affected lot numbers are 17241278, 17241297, 17241304, 17241315, and 17241327, all with expiration dates of July 2026. The product was distributed nationwide in the United States.
Consumers with bottles from these lot numbers should contact their pharmacy or healthcare provider for guidance.
The recalled product
- Product
- CLINDAMYCIN HYDROCHLORIDE (CLINDAMYCIN HYDROCHLORIDE)
- Brand
- CLINDAMYCIN HYDROCHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot # 17241278
- exp. date Jul-26 17241297
- exp. date Jul-26 17241304
- exp. date Jul-26 17241315
- exp. date Jul-26 17241327
- exp. date Jul-26
UPCs (3)
- 0368462142011
- 0368462143018
- 0368462144015
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27